FilingsTodayBioNote
At a glance
BioNote filed 39 disclosures in the last 12 months, including 4 insider, 3 earnings, 2 5% holder and 2 buyback. The most recent key filing was on Aug 6.
Revenue for 2025 was ₩118B, up 15.1% on 2024. Operating margin was 14.1% against 11.9% a year earlier. Debt was 3% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩68.9B and operating profit of ₩14.8B.
The 2025 annual report lists 334 employees with an average tenure of 4.8 years and average pay of ₩49.2M, #1488 of 1,829 listed companies by average pay. Its 8 directors and auditors were paid ₩232M each on average. It paid ₩228 per common share in cash dividends, against ₩200 a year earlier (+14%). 조영식 and related parties held 73.21% at year end.
From the 2025 annual report
Staff: 334 (130 men, 204 women), of whom 24 on fixed-term contracts. Total pay for the year: ₩18B. Directors and auditors: 8, paid ₩1.9B in total.
Dividends (common shares)
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash dividend per share | ₩228 | ₩200 | ₩200 |
| Payout ratio | - | 36.7% | - |
| Yield (as filed) | 3.83% | 4.15% | 4.70% |
| Total cash dividends | ₩22.9B | ₩20.3B | ₩20.4B |
Largest shareholder
조영식 holds 34.99%; with 15 related parties the group holds 73.21% of common shares at year end (from 69.78% at the start of the year).
Individuals paid ₩500M or more
| 조병기 대표이사 | ₩590M |
| 조영식 의장 | ₩589M |
Auditor: 한영회계법인 · opinion: Unqualified.
Rankings: Low debt #1 of 1,372
Source: 2025 annual business report (DART). How figures are combined
Financial summary
Key filings
Other filings
Links open the original filing on DART, in Korean.